Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Trading innovative ideas for academic bursaries worth R275 000
2015-11-09


The top three individual bursary winners with TATA and UFS representatives. From Left:  Naquita Fernandes, Henrike Prinsloo, Lebohang Motsisi, Stefan Strampe, Dr. Johan van Zyl, Jehan van Vuuren, Sanjeeb Lahiri and Salomien Boshoff.
Photo:  Lize Van Den Berg

Learning from industry experts is essential for students’ development. When that learning eases the financial burden of tuition fees, it is even better. TATA Africa has ensured that students from the University of the Free State (UFS) earn academic currency for displaying leadership and business skills.

Jehan Van Vuuren walked away with R40 000 in his student account, Hendrike Prinsloo earned herself R30 000, Stephan Strampe has R25 000 less to worry about when the 2016 academic year arrives, and seven other students managed to save their parents R20 000 each.

These top 10 Strategic Marketing students from the UFS Department of Business Management and Department of Communication Science took up the challenge of devising strategic concepts to be implemented by the Africa branch of TATA Group companies.

TATA Group is a multinational conglomerate which specialises in a wide range of products and services, such as automobile manufacturing, hotel accommodation, construction, textiles, food and beverages, amongst other enterprises operating under its banner. On 15 October 2015, the company’s Head Office representatives signed a cheque for R275 000 to reward the creative input of our students.

Lesle-Ann George won an academic bursary worth R20 000 for her individual effort, and was also part of one of the best four groups that won R10 000 each. She said the competition was an opportunity of a lifetime. The financial aid will be channeled towards the BCom Marketing Honours degree she intends pursuing next year.

The students’ ideas included market research for TATA motors, the development of a mobile application for the Taj Hotel, as well as innovative student-oriented social media, and guerrilla marketing strategies.

“This collaborative partnership between TATA Africa and UFS has provided the students with an opportunity to learn from key role-players in the industry and, in turn, to gain practical exposure to real-life industry happenings,” said Naquita Fernandes, a Business Management lecturer and the competition’s co-organiser.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept